Abstract 3764: Trabectedin activity in patient-derived mesothelioma xenografts:

@inproceedings{Licandro2016Abstract3T,
  title={Abstract 3764: Trabectedin activity in patient-derived mesothelioma xenografts:},
  author={Simonetta Andrea Licandro and Roberta Frapolli and Ezia Bello and Roberta Libener and Sara Orecchia and Federica Grosso and Maurizio D'Incalci},
  year={2016}
}
Malignant pleural mesothelioma (MPM) incidence is increased over the past two decades and it is predicted to increase further in the next 20 years especially in developing countries where asbestos has not yet been banned. Surgery is not an option for the majority of patients due to the diffuse growth of MPM, making chemotherapy the treatment of choice, but prognosis remains very poor with a median survival time of 10-17 months. Trabectedin (ET-743, Yondelis) is a marine alkaloid used for the 2… CONTINUE READING